Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating long-term gantenerumab in Alzheimer's disease has been terminated, and results are now posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Gantenerumab (gantenerumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-05-08